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Abstract: Patients with symptomatic severe aortic stenosis (AS) benefit from aortic valve replacement surgery, but the 
management of patients with asymptomatic severe AS is more controversial. While cholesterol and angiotensin have been 
linked to AS progression, we should await the results of ongoing randomized trials before medical therapy to lower 
cholesterol or inhibit angiotensin can be recommended to limit disease progression. Clinical factors, echocardiographic 
parameters, valve morphology, exercise stress testing results, and cardiac biomarkers may be useful in identifying patients 
who will have early development of symptoms during follow-up and require closer monitoring. The risks associated with 
aortic valve replacement outweigh the benefits in the majority of patients with asymptomatic severe AS. 
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INTRODUCTION 
  Aortic valvular stenosis (AS) develops as a result of 
progressive inflammation and calcification of the valve 
leaflets leading to restriction of leaflet excursion and left 
ventricular outflow obstruction. Normal aortic valve cross 
sectional area is 3.0 to 4.0 cm
2 in adults and a transvalvular 
gradient develops when the orifice area becomes <50% of 
normal. 
  In patients with normal left ventricular systolic function, 
severe AS is defined as a peak AS velocity >4 m/s, a mean 
transaortic pressure gradient >40 mmHg, or an aortic valve 
area (AVA) <1 cm
2. A valve area index <0.6 cm
2/m
2 is also 
indicative of severe AS [1]. 
  This paper focuses on the natural history of AS, 
specifically looking at medical therapy that may slow the 
progression of the disease, and factors that can be used to 
risk stratify patients with asymptomatic severe AS to identify 
those who may benefit from surgical intervention. 
NATURAL HISTORY 
  The natural history of AS begins with a long 
asymptomatic period that is associated with minimal 
mortality. There is significant individual variability in the 
rate of progression of severity of AS. On average, peak 
aortic jet velocity increases by 0.32 ± 0.34 m/s per year, 
mean transaortic pressure gradient increases by 7 ± 7 mmHg 
per year, and AVA decreases by 0.12 ± 0.19 cm
2 per year 
[2]. 
  Symptoms rarely occur until the valve becomes severely 
stenotic. The classic symptoms of AS are exertional angina, 
syncope, and dyspnea (i.e. heart failure). After the onset of 
symptoms the average survival is only 2 to 3 years with a 
high risk of sudden death [3,4]. Patients with symptomatic 
severe AS should undergo aortic valve replacement surgery,  
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because their survival is markedly improved following aortic 
valve replacement.  
  Patients who are asymptomatic have a good prognosis. 
Overall survival in 126 patients with asymptomatic severe 
AS is comparable to age and sex matched controls from the 
general population [5]. The rate of sudden cardiac death is 
rare at <1% per year [2, 5, 6].  
PATHOLOGY 
  In developed countries the great majority of valvular AS 
is caused by calcification of a trileaflet or congenitally 
bicuspid or unicuspid valve [7-9]. While at one time this 
process was thought to be degenerative due to mechanical 
stress and passive calcium accumulation, it is now known to 
be an active one with cellular findings similar to what is seen 
in vascular atherosclerosis. 
  “Early” changes are due to subendocardial thickening 
secondary to chronic inflammation. This involves disruption 
of the basement membrane and cellular infiltration of 
macrophages and T-lymphocytes [10, 11]. There is also 
accumulation of lipids that are deposited on the leaflets and 
are oxidized. This ongoing process eventually leads to 
sclerosis and calcified deposits, particularly on the aortic 
side of the valve [12-15]. Calcific nodules tend to localize in 
the valve pockets and the base of the commissures in 
trileaflet valves and at the raphe and the base of the valve 
pockets in bicuspid valves [12-16]. The end result is 
thickened, stiff leaflets with limited systolic excursion. 
MEDICAL THERAPY 
Hypercholesterolemia 
  Lipids are central to multiple pathways in the 
development of fibrosis and calcification of AS. The lipid 
lowering and anti-inflammatory effects of hydroxymethyl-
glutaryl-coenzyme A reductase inhibitors, or statins, and 
their proven disease modifying ability in atherosclerosis 
make them a potential agent for halting the progression of 
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  Valvular and supravalvular AS are known complications 
of familial hypercholesterolemia [17-20]. An association 
between AS progression and hypercholesterolemia has also 
been shown in both bicuspid and tricuspid valves [21-25]. 
Retrospective studies suggest that statins may slow the rate 
of hemodynamic progression AS [26-29].  
  Prospective studies have shown variable results. The 
RAAVE (Rosuvastatin Affecting Aortic Valve Endothelium) 
study looked at 121 patients with asymptomatic moderate to 
severe AS with aortic valve area of 1.0 to 1.5 cm
2 (average 
peak AS velocity 3.63 m/s; average AVA 1.21 cm
2) [30] and 
followed them for echocardiographic evidence of AS 
progression. This was an open label, prospective study in 
which patients with a low density lipoprotein (LDL) 
cholesterol >3.4 mmol/L were treated with rosuvastatin 
while those with an LDL <3.4 mmol/L received no lipid 
lowering therapy. Over the mean follow-up of 73 weeks 
there was reduced progression of AS in the rosuvastatin 
group compared to the control group (increase in AS 
velocity of 0.04 m/s per year in the rosuvastatin group versus 
0.24 m/s per year in the control group, P=0.007; decrease in 
AVA of 0.05 cm
2 per year in the rosuvastatin group versus 
0.10 cm
2 per year in the control group, P=0.041). 
  The effect of statin treatment on aortic valve calcification 
was prospectively evaluated in 61 patients with AS (mean 
AVA 1.16 cm
2; range 0.7-2.0 cm
2) who underwent baseline 
and one-year echocardiography and electron-beam computed 
tomography [31]. No difference was seen in aortic valve 
calcium in those treated with statin therapy versus those who 
were not treated over the one-year follow-up. 
  Currently, the only published randomized controlled trial 
looking at statin therapy in AS is the SALTIRE study 
(Scottish Aortic Stenosis and Lipid Lowering Trial, Impact 
on Regression) [32]. One hundred and fifty-five patients 
were randomized to atorvastatin 80 mg daily or placebo to 
test the hypothesis that intensive lipid-lowering therapy 
would halt the progression of AS as assessed by aortic jet 
velocity on Doppler echocardiography and aortic valve 
calcium score on computed tomography. Patients with a 
peak AS velocity of 2.5 m/s and aortic valve calcification 
on echocardiography were enrolled. The average peak AS 
velocity was 3.43 m/s, the average AVA was 1.03 cm
2, and 
aortic valve calcium score was 5920 log arbitrary units. 
Thirty-six patients had severe AS based on a peak AS 
velocity 4.0 m/s. Patients were followed for a median of 25 
months. Despite a significant change in the mean LDL 
cholesterol on treatment between the two groups (53% 
decrease in atorvastatin grouped versus no change in placebo 
group, P<0.001), there was no difference in measures of AS 
progression between the two groups (increase in peak aortic 
jet velocity of 0.20 m/s in both groups, P=0.95; increase in 
valvular calcification 22.3% per year in the atorvastatin 
group versus 21.7% per year in the placebo group, P=0.93) 
Fig. (1).  
  This study is limited by a relatively small sample size, 
which was not powered to assess clinical end points or small 
differences in valvular progression, and the large percentage 
of patients with severe AS, who may have too advanced 
disease to be amendable to medical therapy. Finally, patients 
with an LDL 4.0 mmol/L were excluded from SALTIRE, a 
group that might be expected to benefit from statin therapy. 
 
Fig. (1). Progression of AS in patients treated with intensive 
atorvastatin therapy on matched placebo. [from reference 22 with 
permission]. 
  Two larger clinical trials will help clarify this issue. The 
ASTRONOMER trial (The Aortic Stenosis Progression 
Observation: Measuring Effects of Rosuvastatin) has 
completed randomization of patients with mild to moderate 
AS (peak AS velocity 2.5 to 4.0 m/s) independent of valve 
morphology to 40 mg daily of rosuvastatin or placebo with a 
minimum follow-up of 3 years [33]. The SEAS study 
(Simvastatin and Ezetimibe in Aortic Stenosis Study) is 
comparing treatment with ezetimibe/simvastatin 10/40 mg 
daily versus placebo in patients with asymptomatic mild to 
moderate AS (peak AS velocity 2.5 to 4.0 m/s) with a 
minimum 4 years follow-up [34]. Results of both trials are 
expected in late 2008 or early 2009. Until the results of these 
large prospective studies are available, empiric statin therapy 
cannot be endorsed. 
Inhibition of Angiotensin 
  Angiotensin-converting enzyme (ACE) and angiotensin 
II type 1 and type 2 receptors are have been found in stenotic 
aortic valves [35], suggesting that the rennin-angiotensin 
system may play a role in the progression of the disease. 
ACE is found in atherosclerotic lesions and due to 
proinflammatory effects, contributes to the atherosclerosis. 
  Angiotensin inhibition has also been assessed to prevent 
aortic valve disease progression. Two hundred and eleven 
patients with asymptomatic AS with a peak AS velocity of 
>2.5m/s (average peak AS velocity 3.96 m/s; mean AVA 
0.84 cm
2)
  were retrospectively identified and the rates of 
hemodynamic progression of AS were compared between 
patients who were taking an angiotensin converting enzyme 
inhibitor (ACEI) versus those who were not [29]. No 
difference was found (increase in peak AS velocity of 0.29 
m/s per year versus 0.35 m/s per year, respectively, P=0.29). 
This lack of treatment effect with ACEI was independent of 
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  The use of ACEI in preventing aortic valve calcium 
accumulation has also been evaluated. A retrospective 
analysis was performed on 123 patients who had undergone 
serial electron beam computed tomography for coronary 
calcium screening and had aortic valve calcification at 
baseline [36]. At a mean follow-up of 2.6 years, the no-
ACEI group had a significantly higher median rate of 
absolute change in aortic valve calcium score than did the 
ACEI group (P=0.04). 
  While ACEI are generally used cautiously in AS due to 
their vasodilatory properties, they have been shown to be 
safe in mild to moderate AS [37] and have beneficial effects 
on cardiac hemodynamics [38-40], even in patients with 
severe AS. However, no studies have examined the effect of 
ACEI on clinical outcome in asymptomatic AS patients.  
  In summary, there is no prospective data looking at the 
use of ACEI in AS. The limited retrospective data have 
shown contradictory results. Thus, ACEI cannot be 
recommended as therapy for the prevention of the 
progression of AS. 
Bacterial Endocarditis Prophylaxis 
  Recently updated American Heart Association (AHA) 
Guidelines no longer recommend prophylaxis of bacterial 
endocarditis for patients with native valvular disease 
including AS [41]. However, patients should continue to 
maintain optimal dental hygiene including regular cleanings 
to decrease the likelihood of sustained bacteremia. 
Summary of Medical Therapy 
  There is no medical therapy proven to alter the rate of 
progression of AS. Empiric statin therapy cannot be 
recommended. Trials are ongoing which should help clarify 
the role of statins in AS. Only limited data is available on the 
use of ACEI in this population. Prospective studies are 
needed to further assess ACEI in patients with AS. 
RISK STRATIFICATION FOR SURGICAL THERAPY 
Pitfalls of Watchful Waiting 
  ACC/AHA indications for aortic valve replacement in 
patients are as follows [1]: 
•  Symptomatic severe AS 
•  Severe AS in patients undergoing coronary artery 
bypass grafting, other valve surgery, or surgery on 
the ascending aorta 
•  Left ventricular systolic dysfunction (ejection 
fraction <50%) secondary to severe AS 
  Based on these guidelines, patients with asymptomatic 
severe AS are not recommended to undergo valve 
replacement surgery. However, there are concerns with this 
conservative approach and some advocate earlier 
consideration for surgical treatment [42, 43]. While the risk 
is low in the asymptomatic patient there continues to be a 
small risk of sudden cardiac death. In addition, symptoms 
can be subtle or hidden by a reduction in the patient’s 
activity level. Finally, even with a careful watch and wait 
approach, sudden death can occur soon after the onset of 
symptoms, either before the patient seeks medical attention, 
or while waiting for surgery. 
  Thus, an ideal approach to minimize the risk of adverse 
events would be to identify and refer patients for surgery just 
before the onset of symptoms. Various methods have been 
proposed to attempt to identify patients with asymptomatic 
severe AS who are at risk for adverse events. These include 
assessing clinical and hemodynamic predictors, valve 
morphology, exercise stress testing, and the use of cardiac 
biomarkers. 
Clinical/Hemodynamic Predictors 
  One hundred and twenty-three asymptomatic patients 
with a peak AS velocity >2.5m/s and thickened aortic 
leaflets with reduced excursion were followed with regular 
clinical assessment, echocardiography, and exercise 
treadmill testing for 2.5 years to determine prognostic factors 
[2]. Baseline peak AS velocity predicted the likelihood of 
aortic valve replacement. Patients with an AS velocity >4 
m/s have a >50% likelihood of symptom onset or death 
within a 2 year period. Other independent predictors of death 
or aortic valve surgery in multivariate analysis were the rate 
of change of AS velocity over time (P<0.00001) and 
functional status score (P=0.02). 
  A large cohort of patients with asymptomatic severe AS 
with peak AS velocity 4 m/s (average peak AS velocity 4.4 
m/s; mean AVA 0.9 cm
2) were followed for 5.4 years to 
assess the risks and predictors of mortality in asymptomatic 
severe AS [44]. Only AVA (P=0.005) and left ventricular 
hypertrophy (P=0.04) were independent predictors of 
symptom onset, and development of symptoms preceded 
sudden death in all but 11 of 179 patients.  
  In another study of patients with severe AS (peak AS 
velocity >4 m/s), echocardiographic assessment of AS 
severity (AS velocity or AVA) was not predictive of future 
events, nor were any other clinical or hemodynamic 
parameters [5]. 
  A recent prospective study involving 133 asymptomatic 
patients with a peak transaortic pressure gradient 60 mmHg 
and normal left ventricular systolic function found that only 
a reduction in ejection fraction over time (but remaining 
within normal limits) was an independent predictor of 
symptom onset or sudden cardiac death (P=0.001) [45]. 
However, in individual patients the clinical utility of this 
predictor is limited as the change in ejection fraction is small 
and single measurements of ejection fraction have wide 
confidence limits. 
Valve Morphology 
  The ability of valve morphology to predict future events 
was assessed in 128 consecutive patients with asymptomatic 
severe AS (peak AS velocity >4 m/s) [5]. In this group who 
were followed for a mean of 24 months, only the extent of 
valve calcification was an independent predictor of outcome. 
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fewer events (death or aortic valve replacement necessitated 
by the onset of symptoms) than patients with moderate or 
severe calcification (P<0.001) Fig. (2).  
 
Fig. (2). Event-free survival among patients with nor or mild aortic 
valve calcification compared with moderate or severe calcification. 
[from reference 5 with permission]. 
  The combination of moderate to severe valvular 
calcification with a rapid increase in AS velocity was a 
particularly high risk combination. An increase in AS 
velocity of 0.3 m/s per year in the group of patients who 
had moderately or severely calcified valve leaflets predicted 
a 79% likelihood of surgery or death within 2 years of the 
observed increase. The importance of valvular calcification 
as a predictor of the rate of AS progression had also been 
shown when the calcification was determined by 
angiography [46]. 
Exercise Stress Testing 
  Sixty-six patients with asymptomatic severe AS based on 
an AVA <1.0 cm
2 (average peak transaortic gradient 83 
mmHg; mean AVA 0.61 cm
2) underwent treadmill exercise 
stress testing to determine its prognostic value [47]. The 
main outcome measures were development of symptoms or 
sudden cardiac death, and mean follow-up was 15 months. A 
positive stress test was defined as onset of symptoms 
(precordial chest pain or near syncope), significant ST 
depression, complex ventricular arrhythmia, or a failure of a 
systolic blood pressure to rise >20 mmHg during exercise. 
Forty-four patients had a positive test, the majority due to 
symptoms. A positive test was predictive of reaching an 
endpoint (hazard ratio 7.4). Four patients died suddenly, all 
of whom had a positive stress test. 
  One hundred and twenty-five patients with asymptomatic 
moderate to severe AS based on an AVA <1.4 cm
2 (mean 
AVA 0.9 cm
2) underwent exercise treadmill testing and were 
followed for 12 months after the stress test [48]. Endpoints 
were the onset of spontaneous exertional symptoms or 
sudden cardiovascular death. The criteria for a positive stress 
test were the development of limiting symptoms (chest 
discomfort, breathlessness, or dizziness), significant ST 
depression, or no increase in blood pressure at peak exercise 
compared to baseline. Symptoms on stress testing were an 
independent predictor of spontaneous symptoms during 
follow-up (P<0.001). An abnormal blood pressure response 
or ST segment depression did not improve the predictive 
ability of the test. No patients died in follow-up. 
  Exercise echocardiography has been used for risk 
assessment in 69 patients with asymptomatic severe AS 
defined by an AVA 1.0 cm
2  (average peak transaortic 
pressure gradient 65 mmHg; mean AVA 0.81 cm
2) [49]. 
Stress testing was performed using a semi-supine bicycle. 
The combined end-point was the development of symptoms 
(angina, dyspnea, or syncope), hospital admission for heart 
failure, requirement for aortic valve replacement, or cardiac 
death. These patients were followed for 15 months. A 
positive stress test was defined as an onset of symptoms, 
significant ST depression, significant arrhythmia, or a fall or 
small rise (<20 mmHg) in systolic blood pressure as 
compared to baseline. Those who had a normal test had 
increased event free survival when compared to those with 
an abnormal test (P=0.0026). An increase in exercise 
induced mean transaortic pressure gradient of 18 mmHg 
(value determined from receiver-operator characteristic 
curve) was predictive of events (P=0.0015), and provided 
incremental prognostic information to resting echocardio-
graphic and exercise electrocardiographic parameters. 
  Multiple studies have shown that a positive stress test has 
the ability to predict the onset of spontaneous symptom and 
thus requirement for valve replacement surgery [47-51]. The 
majority of abnormal or positive exercise stress test were 
based on symptom onset, which appear to be more predictive 
than other criteria [52]. Electrocardiographic ST depression 
has shown limited ability to predict future events. The high 
incidence of concomitant coronary artery disease in patients 
with AS may have contributed to its poor predictive ability. 
Variable results have been shown for the value of an 
abnormal blood pressure response with exercise to predict 
events [2, 47-51]. Differences in the definition of an 
abnormal blood pressure response and in the mode of stress 
testing (treadmill, upright bicycle, semi-supine bicycle) 
likely contributed to the inconsistent results.  
  Contradictory to conventional opinion, carefully moni-
tored exercise stress testing in patients with severe AS is 
safe. No complications were reported in the studies 
discussed above [47-51] which included 400 patients, most 
of whom had at least moderate AS. Properly monitored 
exercise stress testing is feasible and safe in patients with 
AS, provided that these patients have been stable with no 
overt symptoms of AS. A comprehensive history is a 
prerequisite for exercise testing in these patients.  
Cardiac Biomarkers 
  Brain natriuretic peptide (BNP) is a neurohormone 
secreted by the ventricles in response to volume and pressure 
overload [42, 53]. BNP levels have been used to assess risk 
in patients with heart failure, acute coronary syndromes, and 
chronic severe mitral regurgitation [54-57]. BNP has also 
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  BNP and its aminoterminal portion Nt-BNP are increased 
in patients with symptomatic AS compared to those who are 
asymptomatic. Natriuretic peptides progressively increase 
with higher New York Heart Association functional class 
and with lower AVA [61-66]. These finding have been 
consistently shown in prospective studies. 
  One of these studies involved 130 patients with severe 
AS based upon peak AS velocity >4 m/s and/or an AVA 
<1.0 cm
2 (average peak AS velocity 5 m/s; mean AVA 0.64 
cm
2) [63]. Baseline BNP levels were used to assess symptom 
free survival in the 43 patients who were asymptomatic at 
the time of entry into the study. Patients were followed for 
mean of 377 days and those with a BNP 130 pg/mL or an 
Nt-BNP  80 pmol/L were significantly more likely to 
develop symptoms over the next 6 to 9 months (P<0.001 for 
both). Another study found that a BNP cut-off of 190 
pg/mL provided the best discriminatory value for the 
presence of symptoms [66]. 
  Nt-BNP but not BNP is a predictor of post-operative 
survival in patients who undergo aortic valve replacement 
[63]. In patients with severe AS and/or aortic regurgitation, 
Nt-BNP decreases after successful aortic valve surgery, but 
continues to increase in patients managed conservatively 
[67]. 
  Elevated plasma BNP is clearly associated with AS 
severity and cardiac symptoms in patients with AS. It also 
has prognostic value in patients scheduled to undergo 
surgical treatment. However, there continue to be limitations 
to the utility of BNP. First, BNP values vary with age, sex 
[68], and body mass index [69], and can be elevated in other 
cardiac and non-cardiac conditions [70]. Secondly, optimal 
cut-offs have yet to be established as there is substantial 
overlap in BNP levels between AS patients with or without 
adverse events. Finally, while natriuretic peptides have been 
shown to predict symptoms, they have not yet been proven 
to accurately identify patients who are likely to have an 
adverse event prior to symptom onset. 
SUMMMARY 
  Many features can be used to identify patients with 
asymptomatic severe AS who are likely to develop early 
symptoms (Table 1).  
Table  1. Predictors of Early Development of Symptoms in 
Patients with Asymptomatic Severe AS 
•  Severity of AS 
•  Increased rate of AS progression (0.3 m/s per year) 
•  Moderate to severe valvular calcification 
•  Abnormal exercise stress test, particularly due to symptoms 
•  Increased mean transaortic pressure gradient >18 mmHg with 
exercise 
•  Elevated BNP 130 pg/mL or Nt-BNP 80 pmol/L 
 
  In deciding whether to perform aortic valve replacement 
in asymptomatic patients with severe AS, the risk of not 
operating compared to the risk of surgery must be 
considered. Limitations associated with watchful waiting 
include the subjectivity of patients’ symptoms, concern 
about sudden death, and the risk of asymptomatic left 
ventricular systolic dysfunction. However, as earlier 
discussed, many papers have shown that the risk of sudden 
death is quite low at <1% per year [2, 5-6, 47-51]. So, 
despite the subjectivity and variability of patients’ 
symptoms, it remains the best indicator for the need for 
aortic valve replacement. Asymptomatic left ventricular 
systolic dysfunction is an uncommon indication for surgery. 
When present, aortic valve replacement typically results in 
restoration of systolic function. 
  Operative mortality for isolated aortic valve replacement 
is 3-4% [60, 71], higher than the risk of sudden death in 
asymptomatic patients. The rate of late annual mortality (>4 
weeks post-operative) in patients with aortic valve 
replacement has been reported at 3.6%, with 24% of those 
deaths attributable to sudden cardiac death [72]. In addition, 
there is morbidity associated with a prosthesis including 
prosthesis dysfunction, valve thrombosis, endocarditis, 
embolism, and the risks associated with anticoagulation. The 
combined risk of these complications for an aortic prosthesis 
is >2% per year [73, 74]. Thus, in the great majority of 
patients the risks of aortic valve replacement surgery and 
potential long-term complications of a prosthesis are greater 
than the risks of careful monitoring of asymptomatic severe 
AS. 
  Assessment of patients with equivocal symptoms, such as 
those who are sedentary or whose history is unreliable can be 
challenging. In this subgroup, the markers listed in Table 1 
may be useful. In particular, serious consideration should be 
given to performing a carefully monitored exercise test 
which has been shown to be safe, clarifies the symptomatic 
state, and provides useful hemodynamic information 
predictive of prognosis.  
CONCLUSIONS 
  The progression of AS is highly variable. At this point 
there are no medical therapies that have been proven to delay 
the progression of AS. Aortic valve replacement is indicated 
for patients with symptomatic severe AS. In the great 
majority of patients with asymptomatic severe AS, the risk 
of surgery outweighs the risk of watchful waiting. There are 
clinical, echocardiographic and biochemical indicators which 
can help identify those likely to develop symptoms. A 
carefully monitored stress test appears safe and useful in 
patients with equivocal symptoms. 
REFERENCES 
[1]   Bonow RO, Carabello BA, Chattejee K, et al. ACC/AHA 2006 
guidelines for the management of patients with valvular heart 
disease. A report of the American College of Cardiology/American 
Heart Association Task Force on Practice Guidelines. J Am Coll 
Cardiol 2006; 48: e1-148. 
[2]   Otto CM, Burwash IG, Legget ME, et al. Prospective study of 
asymptomatic valvular aortic stenosis: clinical, echocardiographic, 
and exercise predictors of outcome. Circulation 1997; 95: 2262-70. 
[3]   Ross J Jr, Braunwald E. Aortic stenosis. Circulation 1968; 38(suppl 
5): 561-7. 
[4]   Horstkotte D, Loogen F. The natural history of aortic valve 
stenosis. Eur Heart J 1988; 9(suppl E); 57-64. 34    Current Cardiology Reviews, 2009, Vol. 5, No. 1  Stewart and Chan 
 
[5]   Rosenhek R, Binder T, Porenta G, et al. Predictors of outcome in 
severe, asymptomatic aortic stenosis. N Engl J Med 2000; 343: 
611-7. 
[6]   Kelly TA, Rothbart RM, Cooper CM, et al. Comparison of 
outcome of asymptomatic to symptomatic patients older than 20 
years of age with valvular aortic stenosis. Am J Cardiol 1988; 61: 
123-30. 
[7]   Davies MJ, Treasure T, Parker DJ. Demographic characteristics of 
patients undergoing aortic valve replacement for stenosis: relation 
to valve morphology. Heart 1996; 75: 174-8. 
[8]   Subramanian R, Olson LJ, Edwards WD. Surgical pathology of 
pure aortic stenosis: a study of 374 cases. Mayo Clin Proc 1984; 
59: 683-90. 
[9]   Peterson MD, Roach RM, Edwards JE. Types of aortic stenosis in 
surgically removed valves. Arch Pathol Lab Med 1985; 109: 829-
32. 
[10]   Otto CM, Kuusisto J, Reichenback DD, Gown AM, O’Brien KD. 
Characterization of the early lesion of ‘degenerative’ valvular 
aortic stenosis: histological and immunohistochemical studies. 
Circulation 1994; 90: 844-53. 
[11]   Warren BA, Yong JLC. Calcification of the aortic valve: its 
progression and grading. Pathology 1997; 29: 360-8. 
[12]   Angelini A, Basso C, Grassi G, Casarotto D, Thiene G. Surgical 
pathology of valve disease in the elderly. Ageing 1994; 6: 225-37. 
[13]   Pomerance A. The pathogenesis of aortic stenosis and its relation to 
age. Br Heart J 1972; 34: 569-74. 
[14]   Roberts C. The congenitally bicuspid aortic valve: a study of 85 
autopsy cases. Am J Cardiol 1970; 26: 72-83. 
[15]   Campbell R. Calcific aortic stenosis and congenital bicuspid aortic 
valves. Br Heart J 1968; 30: 606-16. 
[16]   Chan KL. Is aortic stenosis a preventable disease? J Am Coll 
Cardiol 2003; 42: 593-9. 
[17]   Barr DP, Rothbard S, Eder HA. Atherosclerosis and aortic stenosis 
in hypercholesterolemic xanthomatosis. JAMA 1954; 156: 943-7. 
[18]   Boas EP, Elster SK, Adlersberg D. Calcific aortic stenosis: study of 
serum cholesterol with observation on calcific aortic stenosis in 
familial xanthomatous hypercholesterolemia. Am Heart J 1965; 48: 
485-96. 
[19]   Stanley P, Chartland C, Davington A. Acquired aortic stenosis in a 
twelve-year old girl with xanthomatosis: successful surgical 
correction. N Engl J Med 1965; 273: 1378-80. 
[20]   Rothbard S, Hagstrom JWC, Smith JP. Aortic Stenosis and 
myocardial infarction in hypercholesterolemic xanthomatosis. Am 
Heart J 1967; 73: 687-92. 
[21]   Stewart BF, Siscovick D, Lind BK, et al. Clinical factors associated 
with calcific aortic valve disease. J Am Coll Cardiol 1997; 3: 630-
4. 
[22]   Palta S, Pai AM, Gill KS, Pai RG. New insights into the 
progression of aortic stenosis: implications for secondary 
prevention. Circulation 2000; 101: 2497-502. 
[23]   Nassimiha D, Aronow WS, Ahn C, Goldman ME. Association of 
coronary risk factors with progression of valvular aortic stenosis in 
older persons. Am J Cardiol 2001; 87: 1313-4. 
[24]   Ghani M, Burwash I, Woodend K, Chan K. Case-controlled study 
to assess risk factors for aortic stenosis in congenitally bicuspid 
aortic valve. Am J Cardiol 2001; 88: 690-3. 
[25]   Chui MC, Newby DE, Panarelli M, et al. Association between 
calcific aortic stenosis and hypercholesterolemia: is there a need for 
a randomized controlled trial of cholesterol-lowering therapy? Clin 
Cardiol 2001; 24: 52-5. 
[26]   Wilbert S. Aronow WS, Ahn C, et al. Association of coronary risk 
factors and use of statins with progression of mild valvular aortic 
stenosis in older persons. Am J Cardiol 2001; 88: 693-5. 
[27]   Novaro GM, Tiong IY, Pearce GL, et al. Effect of 
hydroxymethylglutaryl coenzyme A reductase inhibitors on the 
progression of calcific aortic stenosis. Circulation 2001; 104: 2205-
9. 
[28]   Bellamy MF, Pellikka PA, Klarich KW, et al. Association of 
cholesterol levels, hydroxymethylglutaryl coenzyme-a reductase 
inhibitor treatment, and progression of aortic stenosis in the 
community. J Am Coll Cardiol 2002; 40: 1723-30. 
[29]   Rosenhek R, Rader F, Loho N, et al. Statins but not angiotensin 
converting enzyme inhibitors delay progression of aortic stenosis. 
Circulation 2004; 110: 1291-5. 
[30]   Moura LM, Ramos SF, Zamorano SL, et al. Rosuvastatin affecting 
aortic valve endothelium to slow the progression of aortic stenosis. 
J Am Coll Cardiol 2007; 49: 554-61. 
[31]   Mohler ER 3
rd, Wang H, Medenilla E, Scott C. Effect of statin 
treatment on aortic valve and coronary artery calcification. J Heart 
Valve Dis 2007; 16: 378-86. 
[32]   Cowell SJ, Newby DE, Prescott RJ, et al. A randomized trial of 
intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J 
Med 2005; 352: 2389-97. 
[33]   Chan KL, Teo T, Tam J, Dumesnil LG. Rationale, design, and 
baseline characteristics of a randomized trial to assess the effect of 
cholesterol lowering on the progression of aortic stenosis: 
(ASTRONOMER) trial. Am Heart J 2007; 153: 925-31. 
[34]   Rossebo AB, Pedersen TR, Allen C, et al. Design and baseline 
characteristics of the simvastatin and ezetimibe in aortic stenosis 
(SEAS) study. Am J Cardiol 2007; 99: 970-3. 
[35]   O’Brien KD, Shavelle DM, Caulfield MT, et al. Association of 
angiotensin-converting enzyme with low-density lipoprotein in 
aortic valvular lesions and in hman plasma. Circulation 2002; 106: 
2224-30. 
[36]   O’Brien KD, Probstfield JL, Caulfield MT, et al. Angiotensin-
converting enzyme inhibitors and change in aortic valve calcium. 
Arch Intern Med 2005; 165: 858-62. 
[37]   O'Brien KD, Zhao XQ, Shavelle DM, et al. Hemodynamic effects 
of the angiotensin-converting enzyme inhibitor, ramipril, in 
patients with mild to moderate aortic stenosis and preserved left 
ventricular function. J Investig Med 2004; 52: 185-91. 
[38]   Grace AA, Brooks NH, Schofield PM. Beneficial clinical and 
haemodynamic effects of captopril in severe symptomatic aortic 
stenosis. Eur Heart J 1991; 12(Suppl): 740. 
[39]   Friedrich SP, Lorell BH, Rousseau MF, et al. Intracardiac 
angiotensin-converting enzyme inhibition improves diastolic 
function in patients with left ventricular hypertrophy due to aortic 
stenosis. Circulation 1994; 90: 2761-71. 
[40]   Martinez SC, Henne O, Arceo A, et al. Hemodynamic effects of 
oral captopril in patients with critical aortic stenosis. Arch Inst 
Cardiol Mex 1996; 66: 322-30. 
[41]   Wilson W, Taubert KA, Gewitz M, et al. Prevention of infective 
endocarditis. Guidelines from the American Heart Association. A 
guideline from the American Heart Association rheumatic fever, 
endocarditis, and Kawasaki disease committee, council of 
cardiovascular disease in the young, and the council on clinical 
cardiology, council on cardiovascular surgery and anesthesia, and 
the quality of care and outcomes research interdisciplinary working 
group. Circulation 2007; 116: 1736-54. 
[42]   Cheitlin MD. Asymptomatic adults patients with aortic stenosis: 
should they ever have aortic valve replacement? Am Heart Hosp J 
2005; 3: 243-6. 
[43]   Baumgartner H. Management of asymptomatic aortic stenosis: how 
helpful is exercise testing? Eur Heart J 2005; 26:1252-4. 
[44]   Pellikka PA, Sarano, ME, Nishimura RA, et al. Outcome of 622 
adults with asymptomatic, hemodynamically significant aortic 
stenosis during prolonged follow-up. Circulation 2005; 111: 3290-
5. 
[45]   Avakian SD, Grinberg M, Ramires JAF, Mansur AP. Outcome of 
adults with asymptomatic severe aortic stenosis. Int J of Cardiol 
2008; 123: 322-7. 
[46]   Piper C, Bergemann R, Schulte HD, et al. Can progression of 
valvar aortic stenosis be predicted accurately? Ann Thorac Surg 
2003; 76: 676-80. 
[47]   Amato MCM, Moffa PJ, Werner KE, Ramires JAF. Treatment 
decision in asymptomatic aortic valve stenosis: role of exercise 
testing. Heart 2001; 86: 381-6. 
[48]   Das P, Rimington H, Chambers J. Exercise testing to stratify risk in 
aortic stenosis. Eur Heart J 2005; 26: 1309-13.  
[49]   Lancellotti P, Lebois F, Simon M, et al. Prognostic importance of 
quantitative exercise doppler echocardiography im asymptomatic 
valvular aortic stenosis. Circulation 2005; 112: I377-82. 
[50]   Alborino D, Hoffman JL, Fournet PC, Bloch A. Value of exercise 
testing to evaluate the indication for surgery in asymptomatic 
patients with valvular aortic stenosis. J Heart Valve Dis 2002; 11: 
204-9. 
[51]   Peidro R, Brion G, Angelino A. Exercise testing in asymptomatic 
aortic stenosis. Cardiology 2007; 108: 258-64. 
[52]   Pierard LA, Lancellotti P. Stress testing in valve disease. Heart 
2007; 93: 766-72. Management of Asymptomatic Severe Aortic Stenosis  Current Cardiology Reviews, 2009, Vol. 5, No. 1    35 
 
[53]   Iwanaga Y, Nishi I, Furuichi S, et al. B-type natriuretic peptide 
strongly reflects diastolic wall stress in patients with chronic heart 
failure: comparison between systolic and diastolic heart failure. J 
Am Coll Cardiol 2006; 47: 742-8. 
[54]   Harrison A, Morrison LK, Krishnaswamy P, et al. B-type 
natriuretic peptide predicts future cardiac events in patients 
presenting to the emergency department with dyspnea. Ann Emerg 
Med 2002; 39: 131-8. 
[55]   Berger R, Huelsman M, Strecker K, et al. B-type natriuretic peptide 
predicts sudden death in patients with chronic heart failure. 
Circulation 2002; 105: 2392-7. 
[56]   de Lemos JA, Morrow DA, Bentley JH, et al. The prognostic value 
of B-type natriuretic peptide in patients with acute coronary 
syndromes. N Engl J Med 2001; 345: 1014-21. 
[57]   Detaint D, Messika-Zeitoun D, Avierinos JF, et al. B-type 
natriuretic peptide in organic mitral regurgitation: determinants and 
impact on outcome. Circulation 2005; 111: 2391-7. 
[58]   Qi W, Mathisen P, Kjekshus J, et al. Natriuretic peptides in patients 
with aortic stenosis. Am Heart J 2001; 142: 725-2. 
[59]   Prasad N, Bridges AB, Lang CC, et al. Brain natriuretic peptide 
concentrations in patients with aortic stenosis. Am Heart J 1997; 
133: 477-9. 
[60]   Talwar S, Downie PF, Squire IB, et al. Plasma N-terminal pro BNP 
and cardiotrophin-1 are elevated in aortic stenosis. Eur J Heart Fail 
2001; 3: 15-9. 
[61]   Gerber IL, Stewart RAH, Legget ME, et al. Increased plasma 
natriuretic peptide levels reflect symptom onset in aortic stenosis. 
Circulation 2003; 107: 1884-90. 
[62]   Lim P, Monin JL, Monchi M, et al. Predictors of outcome in 
patients with severe aortic stenosis and normal left ventricular 
function: role of B-type natriuretic peptide. Eur Heart J 2004; 25: 
2048-53. 
[63]   Bergler-Klein J, Klaar U, Heger M, et al. Natriuretic peptides 
predict symptom-free survival and postoperative outcome in severe 
aortic stenosis. Circulation 2004; 109: 2302-8. 
[64]   Weber M, Arnold R, Rau M, et al. Relation of N-terminal pro-B-
type natriuretic peptide to severity of valvular aortic stenosis. Am J 
Cardiol 2004; 94: 740-5. 
[65]   Gerber IL, Leggett ME, West TM, et al. Usefulness of serial 
measurement of N-terminal pro-brain natriuretic peptide plasma 
levels in asymptomatic patients with aortic stenosis to predict 
symptomatic deterioration. Am J Cardiol 2005; 95: 898-901. 
[66]   Nessmith MG, Fukuta H, Brucks S, Little WC. Usefulness of an 
elevated B-type natriuretic peptide in predicting survival in patients 
with aortic stenosis treated without surgery. Am J Cardiol 2005; 
96: 1445-8. 
[67]   Weber M, Arnold R, Rau M, et al. Relation of N-terminal pro B-
type natriuretic peptide to progression of aortic valve disease. Eur 
Heart J 2005; 26: 1023-30. 
[68]   Redfield MM, Rodeheffer RJ, Jacobsen SJ, et al. Plasma brain 
natriuretic peptide concentration: impact of age and gender. J Am 
Coll Cardiol 2002; 40: 976-82. 
[69]   Krauser DG, Lloyd-Jones DM, Chae CU, et al. Effect of body mass 
index on natriuretic peptide levels in patients with acute congestive 
heart failure: A ProBNP Investigation of Dyspnea in the 
Emergency Department (PRIDE) substudy. Am Heart J 2005; 149: 
744-50. 
[70]   McKie PM, Burnett JC Jr. B-type natriuretic peptide as a biomarker 
beyond heart failure: speculations and opportunities. Mayo Clin 
Proc 2005; 80: 1029-36. 
[71]   Edwards FH, Peterson ED, Coombs LP, et al. Prediction of 
operative mortality after valve replacement surgery. J Am Coll 
Cardiol 2001; 37: 885-92. 
[72]   Foppl M, Hoffman A, Amann FW, et al. Sudden cardiac death after 
aortic valve surgery: incidence and concomitant factors. Clin 
Cardiol 1989; 12: 202-7. 
[73]   Vongpatanasin W, Hillis LD, Lange RA. Prosthetic heart valves. N 
Eng J Med 1996; 335: 407-16. 
[74]   Aupart MR, Sirinelli AL, Diemont FF, Meurisse YA, Dreyfus XB, 
Marchand MA. The last generation of pericardial valves in the 
aortic position  : ten-year follow-up in 589 patients. Ann Thorac 
Surg 1996; 61: 615-20. 
 
Received: 27 May, 2008  Revised: 05 July, 2008  Accepted: 05 July, 2008 
 